Archive for category Pharma/Biotech – National News

Check Out Bruker’s NEW Pharma Website!

Leave a comment

Press Release: Bruker launches new BRAVO Handheld Raman Spectrometer

March 9th, 2015 – Ettlingen, GermanyBRAVO

BRAVO™: The first next-generation, hand-held Raman spectrometer with patented fluorescence mitigation SSETM (Sequentially Shifted Excitation) now enables measurements of a wider range of raw materials, compared to first-generation systems. Specifically designed for the pharmaceutical industry, BRAVO’s intuitive user interface and touchscreen provide a superior guided workflow. BRAVO features Duo LASER excitation with two wavelengths resulting in high sensitivity across the largest spectral range. Additional features include automated wavenumber calibration for highly precise measurements and the automated measuring tip recognition IntelliTip™, which ensures that the proper measuring tip is used. BRAVO is a handheld Raman spectrometer that is certified as class 1M Laser product for all measurement modes, making training and operations easier and safer. More…

Leave a comment

Bruker Optics’ Matrix-F is featured in a Case Study by Actavis Pharma Inc.

Realizing Process Analytical Technology (PAT) in Process Development by Implementation of Near-Infrared (NIR) Spectroscopy

by Michael Fowler, Janssen Vanderhooft, and Venkatesh Subramanyan
Article published in Pharmaceutical Engineering Magazine, September/October 2013

Topical Gel Background

One critical activity common to most transdermal products is the development and optimization of mix processes for semi-solid, liquid solutions, gels, emulsions, and suspen­sions. Some Critical Quality Attributes (CQAs) for transder­mal products at the mix stage are assay, content uniformity, viscosity, specific gravity, solvent content, and pH. Each of these CQAs has the potential to be monitored by PAT. Although NIR spectroscopy is capable of measuring many quality attributes, only content uniformity and viscosity were characterized in the study discussed in this study. To simplify the discussion of the mix process, any activity related to mixing, blending, homogenizing, or similar will simply be referred to as mixing. Mix processes for topical gel emulsions and suspensions can be particularly challenging to develop.7 Determining mix end points by visual examination is virtually impossible be­ cause products are often opaque; therefore, samples must be collected at discrete intervals for testing CQAs. In addition, the resources required to test these in-process samples make this approach less desirable. There are often mix stages be­tween individual ingredient additions, further increasing the number of experiments that must be conducted to determine mix end points. PAT instrumentation allows these experi­ments to be conducted continuously, providing real-time feedback during the development mix process. The topical gel formulation for this study was comprised of typical com­ponents with common pharmaceutical functions, including solvents, Active Pharmaceutical Ingredients (APis), preser­vatives, gelling agents, emulsifiers, and enhancers. A Bruker Optics, Inc. NIR Matrix-F spectrometer and probe was used for this study. A Charles Ross & Son Company 15 gallon stainless steel multiple-shaft mixer was used for gel mixing.

Request a copy of the entire case study article:



Leave a comment